Cargando…
Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir
Pimodivir exerts an antiviral effect on the early stages of influenza A virus replication by inhibiting the cap-binding function of polymerase basic protein 2 (PB2). In this study, we used a combination of sequence analysis and phenotypic methods to evaluate pimodivir susceptibility of influenza A v...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978222/ https://www.ncbi.nlm.nih.gov/pubmed/33581212 http://dx.doi.org/10.1016/j.antiviral.2021.105035 |
_version_ | 1784680929431650304 |
---|---|
author | Patel, Mira C. Chesnokov, Anton Jones, Joyce Mishin, Vasiliy P. De La Cruz, Juan A. Nguyen, Ha T. Zanders, Natosha Wentworth, David E. Davis, Todd C. Gubareva, Larisa V. |
author_facet | Patel, Mira C. Chesnokov, Anton Jones, Joyce Mishin, Vasiliy P. De La Cruz, Juan A. Nguyen, Ha T. Zanders, Natosha Wentworth, David E. Davis, Todd C. Gubareva, Larisa V. |
author_sort | Patel, Mira C. |
collection | PubMed |
description | Pimodivir exerts an antiviral effect on the early stages of influenza A virus replication by inhibiting the cap-binding function of polymerase basic protein 2 (PB2). In this study, we used a combination of sequence analysis and phenotypic methods to evaluate pimodivir susceptibility of influenza A viruses collected from humans and other hosts. Screening PB2 sequences for substitutions previously associated with reduced pimodivir susceptibility revealed a very low frequency among seasonal viruses circulating in the U.S. during 2015–2020 (<0.03%; 3/11,934) and among non-seasonal viruses collected in various countries during the same period (0.2%; 18/8971). Pimodivir potently inhibited virus replication in two assays, a single-cycle HINT and a multi-cycle FRA, with IC(50) values in a nanomolar range. Median IC(50) values determined by HINT were similar for both subtypes of seasonal viruses, A(H1N1)pdm09 and A(H3N2), across three seasons. Human seasonal viruses with PB2 substitutions S324C, S324R, or N510K displayed a 27–317-fold reduced pimodivir susceptibility by HINT. In addition, pimodivir was effective at inhibiting replication of a diverse group of animal-origin viruses that have pandemic potential, including avian viruses of A(H5N6) and A(H7N9) subtypes. A rare PB2 substitution H357N was identified in an A(H4N2) subtype poultry virus that displayed >100-fold reduced pimodivir susceptibility. Our findings demonstrate a broad inhibitory activity of pimodivir and expand the existing knowledge of amino acid substitutions that can reduce susceptibility to this investigational antiviral. |
format | Online Article Text |
id | pubmed-8978222 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-89782222022-04-04 Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir Patel, Mira C. Chesnokov, Anton Jones, Joyce Mishin, Vasiliy P. De La Cruz, Juan A. Nguyen, Ha T. Zanders, Natosha Wentworth, David E. Davis, Todd C. Gubareva, Larisa V. Antiviral Res Article Pimodivir exerts an antiviral effect on the early stages of influenza A virus replication by inhibiting the cap-binding function of polymerase basic protein 2 (PB2). In this study, we used a combination of sequence analysis and phenotypic methods to evaluate pimodivir susceptibility of influenza A viruses collected from humans and other hosts. Screening PB2 sequences for substitutions previously associated with reduced pimodivir susceptibility revealed a very low frequency among seasonal viruses circulating in the U.S. during 2015–2020 (<0.03%; 3/11,934) and among non-seasonal viruses collected in various countries during the same period (0.2%; 18/8971). Pimodivir potently inhibited virus replication in two assays, a single-cycle HINT and a multi-cycle FRA, with IC(50) values in a nanomolar range. Median IC(50) values determined by HINT were similar for both subtypes of seasonal viruses, A(H1N1)pdm09 and A(H3N2), across three seasons. Human seasonal viruses with PB2 substitutions S324C, S324R, or N510K displayed a 27–317-fold reduced pimodivir susceptibility by HINT. In addition, pimodivir was effective at inhibiting replication of a diverse group of animal-origin viruses that have pandemic potential, including avian viruses of A(H5N6) and A(H7N9) subtypes. A rare PB2 substitution H357N was identified in an A(H4N2) subtype poultry virus that displayed >100-fold reduced pimodivir susceptibility. Our findings demonstrate a broad inhibitory activity of pimodivir and expand the existing knowledge of amino acid substitutions that can reduce susceptibility to this investigational antiviral. 2021-04 2021-02-10 /pmc/articles/PMC8978222/ /pubmed/33581212 http://dx.doi.org/10.1016/j.antiviral.2021.105035 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Patel, Mira C. Chesnokov, Anton Jones, Joyce Mishin, Vasiliy P. De La Cruz, Juan A. Nguyen, Ha T. Zanders, Natosha Wentworth, David E. Davis, Todd C. Gubareva, Larisa V. Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir |
title | Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir |
title_full | Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir |
title_fullStr | Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir |
title_full_unstemmed | Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir |
title_short | Susceptibility of widely diverse influenza a viruses to PB2 polymerase inhibitor pimodivir |
title_sort | susceptibility of widely diverse influenza a viruses to pb2 polymerase inhibitor pimodivir |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978222/ https://www.ncbi.nlm.nih.gov/pubmed/33581212 http://dx.doi.org/10.1016/j.antiviral.2021.105035 |
work_keys_str_mv | AT patelmirac susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT chesnokovanton susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT jonesjoyce susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT mishinvasiliyp susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT delacruzjuana susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT nguyenhat susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT zandersnatosha susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT wentworthdavide susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT davistoddc susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir AT gubarevalarisav susceptibilityofwidelydiverseinfluenzaavirusestopb2polymeraseinhibitorpimodivir |